1. D R . T H E I N T W A I P H Y O
P G 3 , E M
Antepartum Haemorrhage
2. Antepartum haemorrhage (APH) is defined as
bleeding from or in to the genital tract, occurring
from 24+0 weeks of pregnancy and prior to the birth
of the baby.
The most important causes of APH are placenta
praevia and placental abruption.
APH complicates 3–5% of pregnancies
leading cause of perinatal and maternal mortality
worldwide
Up to one-fifth of very preterm babies are born in
association with APH
3. Severity
NO consistent definitions of the severity of APH. It is
recognised that the amount of blood lost is often
underestimated
The amount of blood coming from the introitus may
not represent the total blood lost (for example in a
concealed placental abruption).
It is important to assess for signs of clinical shock
The presence of fetal compromise or fetal demise is
an important indicator of volume depletion
4. Different terminology used
Spotting – staining, streaking or blood spotting
noted on underwear or sanitary protection
Minor haemorrhage – blood loss less than 50 ml
that has settled
Major haemorrhage – blood loss of 50–1000 ml,
with no signs of clinical shock
Massive haemorrhage – blood loss greater than
1000 ml and/or signs of clinical shock.
Recurrent APH - > one occasion.
5. Placenta praevia
Placenta praevia exists when the placenta is inserted
wholly or in part into the lower segment of the
uterus.
classified by ultrasound imaging according to what
is relevant clinically:
if the placenta lies over the internal cervical os -
major praevia;
if the leading edge of the placenta is in the lower
uterine segment but not covering the cervical os,
minor or partial praevia exists
6.
7.
8. Risk factors for placenta praevia
Previous placenta praevia (4-8%)
Previous caesarean sections (risk increased with no. of CS)
Previous termination of pregnancy
Multiparity
Advanced maternal age (>40 years)
Multiple pregnancy
Smoking
Deficient endometrium due to presence or history of:
• uterine scar
• endometritis
• manual removal of placenta
• curettage
• submucous fibroid
Assisted conception
9. Clinical assessment in women presenting with
APH
First and foremost Mother and fetal well being
establish whether urgent intervention is required to
manage maternal or fetal compromise.
The process of triage includes
history taking to assess coexisting symptoms such as
pain,
an assessment of the extent of vaginal bleeding,
the cardiovascular condition of the mother, and an
assessment of fetal wellbeing
10. history should be taken.
pain associated with the haemorrhage.
Placental abruption - continuous.
Labour pain- intermittent.
Risk factors for abruption and placenta praevia should be
identified.
Reduced fetal movements?
If the APH is associated with spontaneous or iatrogenic
rupture of the fetal membranes, bleeding from a ruptured
vasa praevia
Previous cervical smear history -to assess the possibility of
a neoplastic lesion of the cervix
11. Examination of the woman should be performed
to assess the amount and cause of APH
General examination- pulse and blood pressure recorded.
Abdominal palpation
tenderness or signs of an acute abdomen. The tense or
‘woody’ feel to the uterus on abdominal palpation
indicates a significant abruption.
Painless bleeding,high presenting part – placenta praevia
A soft, non-tender uterus may suggest a lower genital
tract cause or bleeding from placenta or vasa praevia.
12. Speculum examination
to identify cervical dilatation or visualise a lower
genital tract cause for the APH.
Digital vaginal examination
If placenta praevia is a possible diagnosis, digital
vaginal examination should not be performed until
an ultrasound has excluded placenta praevia.
13. Investigation
FBC
Coagulation profile
Bd Gp & Rh and cross match
USS –location of placenta
D-dimer
Colour doppler- TVS –VP
In all women who are RhD-negative, a Kleihauer test
should be performed to quantify FMH to gauge the dose
of anti-D Ig required
Fetal monitoring- CTG monitoring
14. Management
If preterm delivery is anticipated, a single course of
antenatal corticosteroid (Dexa 12 mg 12hrly 2 doses)
to women between 24 and 34 wk of gestation
Tocolytics should not be given unless for very
preterm women who need time to transfer to
hospital with NICU
15. For very preterm (24 – 26 wk)
Conservative management – if mother stable
Delivery of fetus – life threatening
At these gestations, experienced neonatologists
should be involved
16. For placenta praevia
Conservative –MacCafee ‘s regime
(Premature < 37 wk ,mother haemodynamically
stable , no active bleeding,fetus stable)
Advise bed rest ,keep pad chart,vital signs
monitoring,USG, Steroids,GSH,daily CTG, and
biophysical profile,Fetal movement count.
Plan for delivery (>37 wk)
Crossmatch 4 U of blood
17. Definitive treatment
Type I, II (ant) ARM +/- oxytocin
If satifactory progress without bleeding VD
If bleeding continue CS
Type II (post ),III, IV CS
18. For Rh negative mother
Anti-D Ig should be given to all non-sensitised RhD-
negative women after any presentation with APH,
independent of whether routine antenatal prophylactic
anti-D has been administered.
In the non-sensitised RhD-negative woman in the
event of recurrent vaginal bleeding after 20+0 weeks
of gestation, anti-D Ig should be given at a minimum
of 6-weekly intervals.
In the non-sensitised RhD-negative woman for all
events after 20+0 weeks of gestation, at least 500 iu
anti-D Ig should be given followed by a test to identify
FMH greater than 4 ml red blood cells; additional anti-
D Ig should be given as required.
19. Complications of APH
Maternal complications
Anaemia
Infection
Maternal shock
Renal tubular necrosis
Consumptive
coagulopathy
Postpartumhaemorrhage
Prolonged hospital stay
Complication of blood
transfusion
Fetal complications
Fetal hypoxia
Small for gestational age
and fetal growth
restriction
Prematurity (iatrogenic
and spontaneous)
Fetal death